Potensi CRISPR-Cas9 Terkonjugasi Sistem Pengantar Vesikel Ekstraseluler sebagai Strategi Terapeutik Penyakit HIV dengan Metode Genome Editing untuk Pengobatan Masa Depan Penyakit HIV
DOI:
https://doi.org/10.32734/scripta.v8i1.26035Keywords:
CRISPR-Cas9, extracellular vesicles, gene therapy, genome editing, HIV, penyaringan genom, terapi gen, vesikel ekstraselulerAbstract
Background: Human Immunodeficiency Virus (HIV) remains a major global health challenge with high morbidity and mortality rates. Although antiretroviral therapy (ART) effectively suppresses viral replication, it is unable to eradicate latent HIV reservoirs, preventing complete viral clearance. Advances in genome editing technologies, particularly Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9 (CRISPR-Cas9), have created new opportunities for HIV treatment through the targeted elimination of integrated viral genetic material.
Objective: This study aimed to review the potential of CRISPR-Cas9 conjugated with extracellular vesicle delivery systems as a therapeutic strategy for HIV based on current scientific evidence.
Methods: A literature review was conducted using scientific articles retrieved from PubMed, ScienceDirect, NCBI, and other relevant scientific databases. Relevant studies were critically reviewed and synthesized to evaluate its therapeutic potential for HIV treatment.
Discussion: The findings indicate that CRISPR-Cas9 can target multiple stages of the HIV life cycle, including disruption of viral entry coreceptors, inhibition of viral replication, and elimination of latent proviral DNA integrated within host genomes. Furthermore, extracellular vesicles offer several advantages as delivery vehicles, including high biocompatibility, low immunogenicity, and efficient intracellular delivery of CRISPR-Cas9 components. Several studies have demonstrated that the combination of CRISPR-Cas9 and extracellular vesicle-based delivery systems can reduce HIV proviral expression and prevent the reactivation of latent viral reservoirs.
Conclusion: CRISPR-Cas9 conjugated with extracellular vesicle delivery systems represents a promising therapeutic approach for HIV treatment. However, further studies are required to evaluate its safety, efficacy, and clinical applicability in humans.
Keywords: CRISPR-Cas9, extracellular vesicles, gene therapy, genome editing, HIV.
Latar Belakang: Human Immunodeficiency Virus (HIV) masih menjadi tantangan kesehatan global dengan angka morbiditas dan mortalitas yang tinggi. Meskipun terapi antiretroviral (ART) efektif dalam menekan replikasi virus, terapi ini belum mampu mengeliminasi reservoir laten HIV sehingga belum dapat memberikan kesembuhan secara menyeluruh. Perkembangan teknologi genome editing, khususnya Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9 (CRISPR-Cas9), membuka peluang baru dalam terapi HIV melalui eliminasi materi genetik virus yang terintegrasi pada genom inang.
Tujuan: Mengkaji potensi CRISPR-Cas9 yang dihantarkan menggunakan vesikel ekstraseluler sebagai strategi terapeutik HIV berdasarkan bukti ilmiah terkini. Metode: Penelitian ini menggunakan metode literature review dengan menelaah berbagai artikel ilmiah yang diperoleh dari PubMed, ScienceDirect, NCBI, dan sumber ilmiah relevan lainnya. Artikel yang relevan ditelaah secara kritis dan disintesis untuk mengevaluasi potensi terapeutik pendekatan tersebut dalam pengobatan HIV.
Pembahasan: Kajian menunjukkan bahwa CRISPR-Cas9 mampu menargetkan berbagai tahap siklus hidup HIV, termasuk menghambat koreseptor masuknya virus, mengganggu replikasi virus, serta mengeliminasi provirus laten yang terintegrasi dalam genom sel inang. Selain itu, vesikel ekstraseluler memiliki keunggulan sebagai sistem penghantar karena bersifat biokompatibel, memiliki imunogenisitas rendah, serta mampu meningkatkan efisiensi pengiriman komponen CRISPR-Cas9 ke sel target. Beberapa penelitian menunjukkan bahwa kombinasi CRISPR-Cas9 dan vesikel ekstraseluler mampu menurunkan ekspresi provirus HIV dan menghambat aktivasi ulang reservoir laten.
Kesimpulan: CRISPR-Cas9 yang dihantarkan menggunakan vesikel ekstraseluler berpotensi menjadi strategi terapeutik inovatif untuk HIV. Meskipun demikian, penelitian lebih lanjut masih diperlukan untuk mengevaluasi keamanan, efikasi, dan aplikasinya pada manusia.
Keyword: CRISPR-Cas9, HIV, penyuntingan genom, terapi gen, vesikel ekstraseluler.
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Muhammad Rizky Hidayatullah, Salwa Adilah Ningtiyas, Adinda Nezma Meidina, Awwa Chaga Qambara Taqwa

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with SCRIPTA SCORE Scientific Medical Journal agree to the following terms:
- Authors retain copyright and grant SCRIPTA SCORE Scientific Medical Journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in SCRIPTA SCORE Scientific Medical Journal.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in SCRIPTA SCORE Scientific Medical Journal.









